Loading...

Second Sight Medical Products

Nasdaq:EYES
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EYES
Nasdaq
$100M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
  • Second Sight Medical Products has significant price volatility in the past 3 months.
EYES Share Price and Events
7 Day Returns
12.4%
NasdaqCM:EYES
2.4%
US Medical Equipment
1.4%
US Market
1 Year Returns
-51.4%
NasdaqCM:EYES
17.5%
US Medical Equipment
4.9%
US Market
EYES Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Second Sight Medical Products (EYES) 12.4% 15% 4.2% -51.4% -76.5% -
US Medical Equipment 2.4% 7.8% 5.1% 17.5% 69.8% 100.9%
US Market 1.4% 3.8% 3.5% 4.9% 44.8% 40.1%
1 Year Return vs Industry and Market
  • EYES underperformed the Medical Equipment industry which returned 17.5% over the past year.
  • EYES underperformed the Market in United States of America which returned 4.9% over the past year.
Price Volatility
EYES
Industry
5yr Volatility vs Market

Value

 Is Second Sight Medical Products undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Second Sight Medical Products. This is due to cash flow or dividend data being unavailable. The share price is $0.8158.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Second Sight Medical Products's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Second Sight Medical Products's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:EYES PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.46
NasdaqCM:EYES Share Price ** NasdaqCM (2019-06-25) in USD $0.82
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 41.37x
United States of America Market PE Ratio Median Figure of 3,095 Publicly-Listed Companies 17.73x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Second Sight Medical Products.

NasdaqCM:EYES PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:EYES Share Price ÷ EPS (both in USD)

= 0.82 ÷ -0.46

-1.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Second Sight Medical Products is loss making, we can't compare its value to the US Medical Equipment industry average.
  • Second Sight Medical Products is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Second Sight Medical Products's expected growth come at a high price?
Raw Data
NasdaqCM:EYES PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
2.4%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 56 Publicly-Listed Medical Equipment Companies 2.32x
United States of America Market PEG Ratio Median Figure of 2,133 Publicly-Listed Companies 1.53x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Second Sight Medical Products, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Second Sight Medical Products's assets?
Raw Data
NasdaqCM:EYES PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.23
NasdaqCM:EYES Share Price * NasdaqCM (2019-06-25) in USD $0.82
United States of America Medical Equipment Industry PB Ratio Median Figure of 183 Publicly-Listed Medical Equipment Companies 4.54x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.79x
NasdaqCM:EYES PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:EYES Share Price ÷ Book Value per Share (both in USD)

= 0.82 ÷ 0.23

3.55x

* Primary Listing of Second Sight Medical Products.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Second Sight Medical Products is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess Second Sight Medical Products's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Second Sight Medical Products has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Second Sight Medical Products expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Second Sight Medical Products expected to grow at an attractive rate?
  • Unable to compare Second Sight Medical Products's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Second Sight Medical Products's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Second Sight Medical Products's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:EYES Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:EYES Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 2.4%
NasdaqCM:EYES Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 42.7%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.9%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.8%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:EYES Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:EYES Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 23 -28 1
2022-12-31 4 -37 1
2021-12-31 1 -37 1
2020-12-31 0 -34 1
2019-12-31 2 -35 1
NasdaqCM:EYES Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 7 -30 -35
2018-12-31 7 -30 -35
2018-09-30 8 -29 -34
2018-06-30 8 -26 -32
2018-03-31 8 -24 -31
2017-12-31 8 -24 -29
2017-09-30 6 -24 -31
2017-06-30 5 -26 -33
2017-03-31 4 -26 -35
2016-12-31 4 -25 -33
2016-09-30 6 -24 -28
2016-06-30 7 -23 -24

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Second Sight Medical Products is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Second Sight Medical Products's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:EYES Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Second Sight Medical Products Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:EYES Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.20 -0.20 -0.20 1.00
2022-12-31 -0.26 -0.26 -0.26 1.00
2021-12-31 -0.27 -0.27 -0.27 1.00
2020-12-31 -0.27 -0.27 -0.27 1.00
2019-12-31 -0.31 -0.31 -0.31 1.00
NasdaqCM:EYES Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.46
2018-12-31 -0.53
2018-09-30 -0.54
2018-06-30 -0.54
2018-03-31 -0.54
2017-12-31 -0.53
2017-09-30 -0.64
2017-06-30 -0.71
2017-03-31 -0.83
2016-12-31 -0.84
2016-09-30 -0.73
2016-06-30 -0.67

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Second Sight Medical Products will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Second Sight Medical Products's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Second Sight Medical Products has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Second Sight Medical Products performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Second Sight Medical Products's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Second Sight Medical Products does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Second Sight Medical Products's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Second Sight Medical Products's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Second Sight Medical Products's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Second Sight Medical Products Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:EYES Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 7.05 -35.04 20.33 13.97
2018-12-31 6.90 -35.09 22.03 14.61
2018-09-30 8.24 -33.65 22.41 14.41
2018-06-30 7.60 -31.84 21.94 13.23
2018-03-31 7.93 -30.72 21.78 12.32
2017-12-31 7.96 -28.52 20.50 10.96
2017-09-30 5.57 -31.48 20.19 10.38
2017-06-30 5.14 -33.25 20.15 10.12
2017-03-31 3.94 -34.91 19.62 8.97
2016-12-31 3.99 -33.18 19.07 8.05
2016-09-30 5.63 -28.28 18.76 6.73
2016-06-30 6.68 -24.46 18.45 6.12
2016-03-31 8.30 -20.88 17.93 6.37
2015-12-31 8.95 -20.02 17.16 6.55
2015-09-30 8.11 -28.12 15.70 7.08
2015-06-30 6.49 -31.10 14.94 7.55
2015-03-31 4.44 -33.72 14.28 7.74
2014-12-31 3.40 -35.20 12.99 7.66
2014-09-30 2.44 -27.60 11.67 7.08
2014-06-30 2.07 -26.13 9.79 6.68
2014-03-31 1.77 -23.96 8.22 6.21
2013-12-31 1.57 -22.97 7.47 6.46
2012-12-31 1.37 -16.28 6.22 6.77

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Second Sight Medical Products has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Second Sight Medical Products has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Second Sight Medical Products improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Second Sight Medical Products's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Second Sight Medical Products has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Second Sight Medical Products's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Second Sight Medical Products's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Second Sight Medical Products is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Second Sight Medical Products's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Second Sight Medical Products's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Second Sight Medical Products has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Second Sight Medical Products Company Filings, last reported 2 months ago.

NasdaqCM:EYES Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 28.53 0.00 31.68
2018-12-31 3.08 0.00 4.47
2018-09-30 3.89 0.00 4.97
2018-06-30 6.54 0.00 7.48
2018-03-31 3.53 0.00 5.01
2017-12-31 7.88 0.00 7.84
2017-09-30 12.97 0.00 13.34
2017-06-30 18.80 0.00 18.13
2017-03-31 24.37 0.00 23.89
2016-12-31 11.15 0.00 10.88
2016-09-30 20.60 0.00 17.82
2016-06-30 28.09 0.00 23.88
2016-03-31 15.94 0.00 10.25
2015-12-31 20.26 0.00 15.96
2015-09-30 24.50 0.00 21.67
2015-06-30 28.10 0.00 26.59
2015-03-31 30.46 0.00 29.74
2014-12-31 34.62 0.00 34.62
2014-09-30 -19.52 25.19 1.67
2014-06-30 -14.47 23.19 6.03
2014-03-31 -14.41 21.20 4.58
2013-12-31 -9.22 19.21 8.67
2012-12-31 -3.04 8.33 4.45
  • Second Sight Medical Products has no debt.
  • Second Sight Medical Products currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Second Sight Medical Products has less than a year of cash runway based on current free cash flow.
  • Second Sight Medical Products has less than a year of cash runway if free cash flow continues to grow at historical rates of 8.1% each year.
X
Financial health checks
We assess Second Sight Medical Products's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Second Sight Medical Products has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Second Sight Medical Products's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Second Sight Medical Products dividends.
If you bought $2,000 of Second Sight Medical Products shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Second Sight Medical Products's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Second Sight Medical Products's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:EYES Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:EYES Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Second Sight Medical Products has not reported any payouts.
  • Unable to verify if Second Sight Medical Products's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Second Sight Medical Products's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Second Sight Medical Products has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Second Sight Medical Products's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Second Sight Medical Products afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Second Sight Medical Products has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Second Sight Medical Products's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jonathan McGuire
COMPENSATION $1,225,105
AGE 55
TENURE AS CEO 3.8 years
CEO Bio

Mr. Jonathan Will McGuire has been the President, Chief Executive Officer and Director at Second Sight Medical Products, Inc. since August 18, 2015. Mr. McGuire was President of Americas Commercial at Volcano Corporation from May 2014 to August 18, 2015 and served as its Senior Vice President and General Manager of Coronary Imaging, Systems and Program Management since March 2013. Mr. McGuire served as Chief Operating Officer of The Spectranetics Corporation from October 6, 2005 to April 2, 2010. He served as President and Chief Executive Officer of AtheroMed, Inc. Prior to joining Volcano, Mr. McGuire served as Vice President and General Manager of Patient Monitoring at Covidien. Mr. McGuire held various positions at Guidant Corporation from 1998 to 2005 including General Manager of Guidant Latin America, Director of U.S. Marketing for Vascular Intervention (VI); Director of Global Marketing for VI; and Production Manager for Coronary Stents. Prior to 1998, Mr. McGuire held positions in Finance and Production at IVAC Medical Systems. He joined The Spectranetics Corp. from Guidant Corporation. He held several marketing positions within Guidant, LLC (alternate name, Guidant's Vascular Intervention Group), including General Manager of Puerto Rico and U.S.V.I from March 2003 to March 2004, Director of U.S. Marketing from March 2002 to March 2003, Director of Global Marketing from May 2001 to March 2002 and Manager of Global Stent Marketing from April 1999 to May 2001. While at Guidant, Mr. McGuire led the development of marketing and sales strategy, resulting in the creation of a premium alloy coronary stent segment. He also launched the Multi-link stent and was responsible for the initiatives that increased Guidant's market share from 45 percent to 50 percent in the highly competitive U.S. stent market. Earlier, he held several management positions in the Vascular Intervention manufacturing division, and was responsible for establishing manufacturing operations in Ireland, which had the capacity to supply 70 percent of Guidant coronary stent and balloon dilatation catheter volumes. Mr. McGuire graduated from the Georgia Institute of Technology with a Bachelor of Civil Engineering and has a Master of Business Administration degree from the University of North Carolina Kenan-Flagler Business School.

CEO Compensation
  • Jonathan's compensation has increased whilst company is loss making.
  • Jonathan's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Second Sight Medical Products management team in years:

1.2
Average Tenure
54.5
Average Age
  • The average tenure for the Second Sight Medical Products management team is less than 2 years, this suggests a new team.
Management Team

Jonathan McGuire

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
55
TENURE
3.8 yrs

John Blake

TITLE
CFO & Corporate Secretary
COMPENSATION
$1M
AGE
42
TENURE
1.3 yrs

Pat Ryan

TITLE
Chief Operating Officer
COMPENSATION
$914K
AGE
57
TENURE
0.8 yrs

Gunnar Bjorg

TITLE

Steve Okland

TITLE
Chief Commercial Officer
COMPENSATION
$616K
AGE
54
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the Second Sight Medical Products board of directors in years:

4.1
Average Tenure
60
Average Age
  • The tenure for the Second Sight Medical Products board of directors is about average.
Board of Directors

Gregg Williams

TITLE
Non-Executive Chairman
COMPENSATION
$84K
AGE
59
TENURE
1.3 yrs

Jonathan McGuire

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
55
TENURE
3.8 yrs

Bill Link

TITLE
Independent Director
COMPENSATION
$91K
AGE
72
TENURE
16.4 yrs

Matt Pfeffer

TITLE
Independent Director
COMPENSATION
$89K
AGE
60
TENURE
4.1 yrs

Aaron Mendelsohn

TITLE
Independent Director
COMPENSATION
$74K
AGE
66
TENURE
21.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Second Sight Medical Products individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
04. Jun 19 Sell Edward Randolph Individual 04. Jun 19 04. Jun 19 -23,586 $0.71 $-16,649
29. Apr 19 Buy Gregg Williams Individual 26. Apr 19 29. Apr 19 12,051 $0.93 $11,155
23. Apr 19 Buy Gregg Williams Individual 22. Apr 19 23. Apr 19 22,914 $0.95 $21,280
16. Apr 19 Buy Gregg Williams Individual 15. Apr 19 16. Apr 19 12,543 $1.08 $13,499
12. Apr 19 Buy Sam B Williams 1995 Generation-Skipping Trust Company 11. Apr 19 12. Apr 19 23,725 $1.07 $25,262
12. Apr 19 Buy Gregg Williams Individual 11. Apr 19 12. Apr 19 23,725 $1.07 $25,262
14. Dec 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 12. Dec 18 12. Dec 18 1,637,550 $0.92 $1,499,996
14. Dec 18 Buy Gregg Williams Individual 12. Dec 18 12. Dec 18 1,637,550 $0.92 $1,499,996
04. Dec 18 Sell Edward Randolph Individual 03. Dec 18 03. Dec 18 -3,733 $1.03 $-3,841
04. Dec 18 Sell Stephen Okland Individual 03. Dec 18 03. Dec 18 -7,764 $1.03 $-7,989
22. Oct 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 18. Oct 18 18. Oct 18 1,233,863 $1.62 $1,998,858
22. Oct 18 Buy Gregg Williams Individual 18. Oct 18 18. Oct 18 1,233,864 $1.62 $1,998,860
16. Oct 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 16. Oct 18 16. Oct 18 4,994 $1.68 $8,410
16. Oct 18 Buy Gregg Williams Individual 16. Oct 18 16. Oct 18 4,994 $1.68 $8,410
09. Oct 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 04. Oct 18 05. Oct 18 13,385 $1.79 $23,376
04. Oct 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 02. Oct 18 03. Oct 18 12,038 $1.81 $21,571
20. Sep 18 Buy Gregg Williams Individual 18. Sep 18 19. Sep 18 14,808 $1.87 $26,952
18. Sep 18 Buy Gregg Williams Individual 14. Sep 18 14. Sep 18 5,100 $1.79 $9,129
18. Sep 18 Buy Gregg Williams Individual 17. Sep 18 17. Sep 18 7,937 $1.79 $14,207
12. Sep 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 11. Sep 18 11. Sep 18 7,938 $1.67 $13,256
12. Sep 18 Buy Gregg Williams Individual 11. Sep 18 11. Sep 18 7,937 $1.67 $13,255
05. Sep 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 04. Sep 18 05. Sep 18 15,414 $1.70 $26,022
01. Sep 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 31. Aug 18 31. Aug 18 7,938 $1.73 $13,741
01. Sep 18 Buy Gregg Williams Individual 31. Aug 18 31. Aug 18 7,937 $1.73 $13,739
30. Aug 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 28. Aug 18 29. Aug 18 14,930 $1.61 $23,899
21. Aug 18 Buy Gregg Williams Individual 20. Aug 18 21. Aug 18 9,992 $1.63 $16,156
18. Aug 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 16. Aug 18 17. Aug 18 9,031 $1.56 $14,073
18. Aug 18 Buy Gregg Williams Individual 16. Aug 18 17. Aug 18 9,032 $1.56 $14,074
16. Aug 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 14. Aug 18 15. Aug 18 1,623,681 $1.56 $2,516,578
16. Aug 18 Buy Gregg Williams Individual 14. Aug 18 15. Aug 18 1,623,681 $1.56 $2,516,578
14. Aug 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 10. Aug 18 13. Aug 18 11,437 $1.60 $17,893
09. Aug 18 Buy Sam B Williams 1995 Generation-Skipping Trust Company 09. Aug 18 09. Aug 18 3,317 $1.54 $5,121
09. Aug 18 Buy Gregg Williams Individual 09. Aug 18 09. Aug 18 3,317 $1.54 $5,121
07. Aug 18 Buy Gregg Williams Individual 06. Aug 18 07. Aug 18 8,074 $1.67 $13,446
24. Jul 18 Buy Gregg Williams Individual 20. Jul 18 23. Jul 18 12,238 $1.67 $20,419
19. Jul 18 Buy Gregg Williams Individual 16. Jul 18 17. Jul 18 12,787 $1.80 $22,815
X
Management checks
We assess Second Sight Medical Products's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Second Sight Medical Products has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Those Who Purchased Second Sight Medical Products (NASDAQ:EYES) Shares Three Years Ago Have A 80% Loss To Show For It

View our latest analysis for Second Sight Medical Products Second Sight Medical Products isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … In the last three years, Second Sight Medical Products saw its revenue grow by 8.6% per year, compound. … Second Sight Medical Products is not the only stock insiders are buying.

Simply Wall St -

What Should Investors Know About The Future Of Second Sight Medical Products, Inc.'s (NASDAQ:EYES)?

The most recent earnings release Second Sight Medical Products, Inc.'s (NASDAQ:EYES) announced in December 2018 … company earnings became less negative compared to the previous year's level

Simply Wall St -

How Should Investors Feel About Second Sight Medical Products, Inc.'s (NASDAQ:EYES) CEO Pay?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Jonathan McGuire's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below US$200m

Simply Wall St -

What Kind Of Shareholders Own Second Sight Medical Products, Inc. (NASDAQ:EYES)?

A look at the shareholders of Second Sight Medical Products, Inc. … With a market capitalization of US$94m, Second Sight Medical Products is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for Second Sight Medical Products

Simply Wall St -

Why Did Second Sight Medical Products Inc's' (NASDAQ:EYES) Insiders Buy Up More Shares?

Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. … Second Sight Medical Products's insiders have invested. … Generally, insiders buying more shares in their own firm sends a bullish signal

Simply Wall St -

When Will Second Sight Medical Products Inc (NASDAQ:EYES) Breakeven?

Second Sight Medical Products Inc's (NASDAQ:EYES):. … Second Sight Medical Products, Inc., together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. … Check out our latest analysis for Second Sight Medical Products

Simply Wall St -

What Is Second Sight Medical Products Inc's (NASDAQ:EYES) Share Price Doing?

Second Sight Medical Products Inc (NASDAQ:EYES), a medical equipment company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM over the last few months. … What does the future of Second Sight Medical Products look like? … With profit expected to grow by 22.24% over the next couple of years, the future seems bright for Second Sight Medical Products.

Simply Wall St -

Company Info

Description

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. It also offers Argus II Retinal Prosthesis System for treating retinitis pigmentosa. The company was founded in 1998 and is headquartered in Sylmar, California.

Details
Name: Second Sight Medical Products, Inc.
EYES
Exchange: NasdaqCM
Founded: 1998
$100,289,853
124,197,961
Website: http://www.secondsight.com
Address: Second Sight Medical Products, Inc.
12744 San Fernando Road,
Suite 400,
Sylmar,
California, 91342,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM EYES Common Stock Nasdaq Capital Market US USD 19. Nov 2014
DB 24P Common Stock Deutsche Boerse AG DE EUR 19. Nov 2014
Number of employees
Current staff
Staff numbers
123
Second Sight Medical Products employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/26 00:54
End of day share price update: 2019/06/25 00:00
Last estimates confirmation: 2019/05/16
Last earnings filing: 2019/05/15
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.